Profusa Executes Significant 1-for-75 Reverse Stock Split

The latest update is out from Profusa ( (PFSA) ).

At a special meeting of stockholders completed on January 27, 2026, Profusa’s shareholders approved an amendment to its certificate of incorporation authorizing a reverse stock split, after which the board delegated to the CEO the authority to set the final terms. The company subsequently implemented a 1-for-75 reverse stock split of its common stock, filing the necessary amendment in Delaware and making the split effective at 12:01 a.m. Eastern Time on February 9, 2026, when its shares began trading on a post-split basis on Nasdaq under the existing ticker PFSA but a new CUSIP. The transaction consolidated every 75 issued and outstanding shares into one share, reduced the number of outstanding common shares from approximately 92.4 million to about 1.2 million while keeping authorized shares at 601 million, proportionally adjusted outstanding equity awards and related plan reserves, and provided for cash in lieu of fractional shares, materially altering the company’s capital structure and share price metrics while leaving total net losses unchanged over the reported historical periods.

More about Profusa

Profusa Inc., based in Berkeley, California, is a commercial-stage digital health company developing tissue-integrated, long-lasting injectable biosensors and an intelligent data platform designed to continuously monitor an individual’s biochemistry and generate medical-grade, personalized data for clinical and personal use. The company, which owns the LUMEE and PROFUSA brands, focuses on next-generation continuous biochemical monitoring technologies for healthcare providers and patients.

Average Trading Volume: 25,907,111

Technical Sentiment Signal: Sell

Current Market Cap: $7.44M

Learn more about PFSA stock on TipRanks’ Stock Analysis page.